Anne Marie Cook - 10 Feb 2026 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: Chief Legal Off. & Corp. Sec.
Issuer ticker: PHAT
Reported as of: 10 Feb 2026
Net transaction value: -$19,679
SEC form: 4
Accepted by SEC: 12 Feb 2026, 16:36:29 UTC
Prior SEC filing: 02 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Anne Marie Cook

Key filing fact

Anne Marie Cook filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 12 Feb 2026.

Key facts

This page summarizes Anne Marie Cook's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 16:36.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: -$19,679.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001320559 Primary reporting owner

Cook Anne Marie

Relationship: Chief Legal Off. & Corp. Sec.
Address: C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK
Signature: /s/ Anne Marie Cook
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHAT transaction

Common Stock

Award

Transaction value: $0
Shares: +3,461
Change %: +4%
Price: $0.000000
Shares after: 90,195
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F2

PHAT transaction

Common Stock

Tax liability

Transaction value: $19,679
Shares: -1,535
Change %: -1.7%
Price: $12.82
Shares after: 88,660
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares issued upon vesting of performance stock units granted to the reporting person on June 23, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.

Footnote F2

Includes 1,722 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.

Footnote F3

Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.